Clarametyx is a company that develops strategies to target infections caused by biofilms. The company aims to combat these infections and reduce antibiotic resistance through their work.

Clarametyx

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

CARB-X

National Institute of Deafness & Communications Disorders (NIDCD)

Rev1 Ventures

Clarametyx Biosciences

Respiratory infections are a serious challenge in people with #cysticfibrosis, as recurring infections and persistent inflammation can cause severe complications and destroy lung tissue. The Cystic Fibrosis Foundation explains why this population is particularly vulnerable to infection and the research underway to address this challenge, including our own anti-biofilm platform.

It’s encouraging to see #Congress dedicating attention to the challenge of #antimicrobialresistance. A bipartisan roundtable last week addressed a variety of measures that can help address this urgent public health threat, including strategies to support novel #innovation like the work we’re doing at Clarametyx. Read more on the discussion and opportunities to accelerate progress.

This critical statistic illustrates why we need to pursue novel approaches to help reduce the morbidity and mortality associated with #CF. We support the Cystic Fibrosis Foundation’s leadership in advocating for everyone affected by this chronic condition. And we're doing our part to introduce #innovation that could help reduce the severity of respiratory infections and improve quality of living for more people with CF. #cysticfibrosis

Learn more about what the Cystic Fibrosis Foundation and others are doing to support clinical trial progress today on #ClinicalTrialsDay.

Clarametyx leaders David V. Richards, Charles McOsker and Steve St. Onge are looking forward to attending #ESCMIDGlobal in Barcelona to connect with academic and industry leaders who are pursuing innovation in the fight against #infectiousdisease and #antibioticresistance.

Today on this “rare” Leap Day, we support the community in recognizing #RareDiseaseDay. This important observance raises awareness of the need for more attention and solutions for disorders like cystic fibrosis (CF), a rare disease affecting just one in 3,200 people in the US. We are doing our part to support advancements for this community through a clinical trial evaluating whether our novel anti-biofilm technology could address infections associated with CF. Share your support for rare diseases today!

Metric
Company Name	Clarametyx
Symbol
MSH ID	COM:CLARAMETYX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	18
Website	clarametyx.com
LinkedIn	clarametyx-biosciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CLAR

COM:CLARAMETYX

Clarametyx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue